Phaseline

Companies › Impact Biotech

Impact Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Padeliporfin VTP
Vascular targeted photodynamic therapy
–Phase 1Locally Advanced Unresectable Pancreatic Adenocarcinoma; Peripheral Lung TumorAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05919238Padeliporfin VTPPhase 1Locally Advanced Unresectable Pancreatic AdenocarcinomaOncologyAug 2027
NCT05918783Padeliporfin VTPPhase 1Peripheral Lung TumorOncologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.